Analyst Rami Katkhuda from LifeSci Capital maintained a Buy rating on Vera Therapeutics and keeping the price target at $70.00.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Rami Katkhuda’s rating is based on several compelling factors that favor Vera Therapeutics. The recent pricing strategy for a competitor’s product, Voyxact, has set a high benchmark in the market, which provides Vera with strategic flexibility in pricing its own product, atacicept. This flexibility could allow Vera to price atacicept competitively, potentially capturing a larger market share. Additionally, the absence of a UPCR threshold on Voyxact’s label, which is expected to be similar for atacicept, increases the potential patient population and commercial opportunity for these therapies.
Furthermore, the market for BLyS and/or APRIL inhibitors in IgAN is expected to grow, with these therapies likely to dominate due to their potential disease-modifying effects. This is supported by recent guidelines and expert opinions. Vera’s strategic positioning and the anticipated approval and launch timeline for atacicept, alongside favorable market conditions, contribute to the positive outlook and the Buy rating assigned by Rami Katkhuda.
Katkhuda covers the Healthcare sector, focusing on stocks such as Viridian Therapeutics, Dianthus Therapeutics, and Vera Therapeutics. According to TipRanks, Katkhuda has an average return of 30.7% and a 55.61% success rate on recommended stocks.
In another report released on November 26, Jefferies also maintained a Buy rating on the stock with a $45.00 price target.